Turn­stone Bi­o­log­ics rides biotech's IPO train in Fri­day de­but

Turn­stone Bi­o­log­ics raised $80 mil­lion in a Fri­day morn­ing IPO un­der the tick­er $TS­BX, book­end­ing a rare two-week stretch for biotech list­ings.

The start­up fol­lows Apogee Ther­a­peu­tics, Sagimet Bio­sciences and 60 De­grees Phar­ma­ceu­ti­cals in go­ing pub­lic in re­cent days, a feat that on­ly a dozen drug de­vel­op­ers have achieved so far this year amid a tur­bu­lent few years for the biotech sec­tor. If un­der­writ­ers ex­er­cise their op­tion to pur­chase more stock, Turn­stone’s IPO would be­come slight­ly larg­er than its $80 mil­lion Se­ries D, an­nounced two years ago to the day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER